Vertex Pharmaceuticals (VRTX) return on invested capital (ROIC)

Return on invested capital · fiscal 2025
27.5%

Vertex Pharmaceuticals (VRTX) earned a return on invested capital of 27.5% in fiscal 2025 (the year ended December 31, 2025). That is 28.8 percentage points higher than the -1.3% of fiscal 2024. Figures as of 17 Nov 2026, 22:27 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on invested capital, fiscal 2025
27.5%
Change on fiscal 2024
+28.8 pts
Highest on record
82.7%fiscal 2022
Lowest on record
-1.3%fiscal 2024
Fiscal years on record
42022–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Vertex Pharmaceuticals return on invested capital (ROIC), in more detail

Across the 4 fiscal years on record (2022–2025), the highest was 82.7% in fiscal 2022 and the lowest -1.3% in fiscal 2024. The fiscal 2025 figure is higher than in 33% of the 3 earlier fiscal years on record, whose median is 43.6%.

History · 4 fiscal years

Return on invested capital by fiscal year

Vertex Pharmaceuticals return on invested capital (ROIC), year by year

Vertex Pharmaceuticals (VRTX) return on invested capital (ROIC) by fiscal year
Fiscal yearReturn on invested capitalChangeYear ended
202527.5% 28.8 pts up
2024-1.3% 44.8 pts down
202343.6% 39.1 pts down
202282.7%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on invested capital is operating income after tax divided by the capital in the business — debt plus equity minus cash — using the company's own tax rate where it is plausible and 21% otherwise, and shown only for the fiscal years in which cash is counted one way.

How to read it

It measures how well the business turns capital into profit whoever supplied it; a figure above the cost of that capital, roughly 8–10%, means growth creates value.

Return on invested capital at health care companies of similar size

Return on invested capital of Vertex Pharmaceuticals and comparable companies
CompanyReturn on invested capitalFiscal year
Pfizer PFE12.7%2025
Danaher DHR5.9%2025
Vertex Pharmaceuticals VRTX27.5%2025
Medtronic MDT7.9%2026
Bristol-Myers Squibb BMY18.9%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on VRTX

Vertex Pharmaceuticals, figure by figure

Vertex Pharmaceuticals (VRTX) overview: price, valuation and scorecardAll health care companies by market value

Vertex Pharmaceuticals return on invested capital (ROIC): questions and answers

What is Vertex Pharmaceuticals's return on invested capital?

Vertex Pharmaceuticals (VRTX) earned a return on invested capital of 27.5% in fiscal 2025 (the year ended December 31, 2025). That is 28.8 percentage points higher than the -1.3% of fiscal 2024.

Is Vertex Pharmaceuticals's return on invested capital high or low compared with its own history?

The fiscal 2025 figure is higher than in 33% of the 3 earlier fiscal years on record, whose median is 43.6%.

What are the highest and lowest return on invested capital figures on record for Vertex Pharmaceuticals?

Across the 4 fiscal years on record (2022–2025), the highest was 82.7% in fiscal 2022 and the lowest -1.3% in fiscal 2024.

How is Vertex Pharmaceuticals's return on invested capital calculated?

Return on invested capital is operating income after tax divided by the capital in the business — debt plus equity minus cash — using the company's own tax rate where it is plausible and 21% otherwise, and shown only for the fiscal years in which cash is counted one way.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Vertex Pharmaceuticals (VRTX) return on invested capital (ROIC)”, data as of 17 November 2026. https://funkfolio.com/stock/VRTX/roic

Underlying data: the company's filings with the SEC and Yahoo Finance.